Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return

Mon, 05th Feb 2024 20:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Requests suspension of trading in company's shares. Warns company is in a highly constrained financial position and requires additional financing urgently, in order to continue as a going concern. Continues to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, but recognises that in the absence of an immediate injection of capital it needs to put staff at risk of redundancy, initiate discussions with its creditors and establish the precise solvency status of the business. Explains should it fail to achieve a solution in the short term, the board would have no option but to place the company into administration.

----------

Gama Aviation PLC - Farnborough, England-based aviation services company - Expects revenue from continuing operations for 2023 of around USD145 million, down from USD168 million in 2022. Predicts adjusted earnings before interest and tax broadly in line with expectations, despite some variances in performance across the business units. Ends year with net cash of USD82 million. Intends to make GBP16.5 million return to shareholders by a tender offer at 95 pence per share as part of a phased cash return.

----------

CEPS PLC - Bath, England-based investment company focussed on industrial sector - Reports trading for 2023 is in line with expectations which would be record results. Adds, all segments have made a solid start to 2024. Expects surplus from wound up pension scheme to total GBP537,086. Estimates receipts, net of tax will be GBP402,815, which will be received in April. Explains this will have a positive impact on the profit and loss account and balance sheet as the surplus on the scheme has not been recognised in the company's accounts. Further, plans to seek approval at a General Meeting for a share capital reduction. In addition, company is considering a recent and alleged claim from a former landlord for dilapidations and CEPS is liaising with its advisers on what it considers to be a more realistic assessment of the liability and quantum, if any.

----------

Sondrel Holdings PLC - Reading, England-based semiconductor design services provider - Confirms receipt of GBP1.5 million of payments in relation to the material turnkey application-specific integrated circuit engagement with an automotive Tier 1 supplier. Says talks with the customer over resolution of the funding for the project extension continue and additional payments are expected in the coming months, assuming completion of the 'tape out' milestone and including the balance of GBP0.2 million. Significant new ASIC business opportunities are in final negotiation for project start in early 2024 and indications remain encouraging that European and US market demand for Sondrel's turnkey ASIC services is strong, company says. Talks ongoing with suppliers to improve the terms of existing supply arrangements. Continues to seek additional capital prior to the end of March 2024 to meet short-term working capital requirements.

----------

Upland Resources Ltd - London-based oil and gas company, which has assets in Malaysia, Tunisia and the UK North Sea - Updates in relation to the Sarawak Block SK334 exploration campaign. Explains pre-drill activities have been identified and a pre-drill work program has been developed to allow early commencement of activities and expedite the drilling program.

----------

Gore Street Energy Storage Fund PLC - investor in utility-scale energy storage projects - Trading update. Reaffirms dividend target of 7% of net asset value for the financial year. Maintains a healthy balance sheet with low debt. At December 31, had GBP66 million in cash or cash equivalents. Operational fleet is on track to more than double by the end of 2024, company says.

----------

Clontarf Energy PLC - lithium and oil gas exploration and production company focused on South American and Africa - Notes the Bolivian State Lithium Co formally launched, on January 26, its second Call for Bids over seven priority salares (salt pans) in Potosi y Oruro. This includes scope for direct lithium extraction proposals and will provide a firm legal basis for work, under Bolivian laws. Says Clontarf has been encouraged to submit bids on further development of the key Uyuni, Coipasa, Pastos Grandes, Capina, Cañapa, Chiguana and Empexa salares. Further, actively participating in the priority European Union lithium initiative. This included a EU delegation to Bolivia and Argentina during November and December 2023, which included several site visits.

----------

Trident Royalties PLC - mining royalty and streaming, providing investment exposure to base, battery, precious and bulk metals - Reports quarterly receipts of USD3.2 million from exposure to gold, copper, and iron ore, a 63% increase from the third quarter, driven principally by seasonally higher deliveries from the gold off-take portfolio. Excluding the Mimbula copper royalty, receipts were slightly above the fourth quarter 2022. Says net debt at December 31 was USD22 million.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Further to announcement on January 31, reports the Court in Lod approved, on February 4, the proposed creditor settlement plan, details of which were announced on January 11. Following this approval, the company can now continue to undertake its business and operations as usual.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.